# Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy

> **NIH NIH R01** · YALE UNIVERSITY · 2024 · $607,955

## Abstract

SUMMARY
While significant progress has been made in the past decade with immunotherapy for metastatic melanoma and
renal cell carcinoma (RCC), not all patients respond, and others develop resistance over time. Hundreds of novel
regimens are being developed to overcome primary and acquired resistance. Some combinations increase the
infiltration of cytotoxic T cells in the tumor to kill cancer cells, while others modulate tumor-associated
macrophages (TAMs) to enhance the T cell activity in the tumor microenvironment. However, toxicity to patients
is an important limitation to immunotherapy regimens. Non-invasive imaging techniques are needed to determine
response to combination therapy to save potential non-responders from unnecessary toxicity. Current imaging
techniques do not assess the dynamic changes in the levels of T cells and TAMs at the same time. The overall
hypothesis is that imaging the infiltration of cytotoxic T cells and TAMs concurrently can better determine
response to immunotherapy regimens.
The goal of this proposal is to develop non-invasive imaging probes for single photon emission computed
tomography (SPECT) imaging of T cells and TAMs concurrently to determine response to combination therapy.
We anticipate that SPECT will accurately recapitulate pathology and may ultimately replace on-treatment
biopsies in patients who might have pseudoprogression. SPECT may also complement tissue-based analyses
to further interrogate the tumor microenvironment through digital spatial profiling (DSP), an in situ profiling
method that preserves spatial information. DSP can quantify multiple biomarkers simultaneously in immune cells
responsible for the tumor’s sensitivity to combination therapy. In our preliminary work we developed the tools to
implement the tracking of CD8+ T cells and CD68+ TAMs in vivo with radiolabeled antibodies. We will test our
SPECT agents in established murine tumor models of melanoma and RCC in mice with intact immune systems.
We will characterize their binding properties to CD8+ T cells and CD68+ TAMs in vitro (Aim 1). We will image
tumoral T cell and TAM infiltration in vivo by SPECT imaging in syngeneic tumor models of melanoma and RCC
and assess activation status of immune cells by DSP after immunotherapy in murine and patient tissues (Aim
2). These studies will lay the foundations for future clinical trials of dual-isotope SPECT in immunotherapy-treated
patients.

## Key facts

- **NIH application ID:** 10781950
- **Project number:** 5R01CA269349-02
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Harriet M. Kluger
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $607,955
- **Award type:** 5
- **Project period:** 2023-02-07 → 2028-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10781950

## Citation

> US National Institutes of Health, RePORTER application 10781950, Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy (5R01CA269349-02). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10781950. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*